##plugins.themes.academic_pro.article.main##
Abstract
The clinical efficacy and safety of riamilovir were assessed based on the results of a study of 150 patients in three compared groups, 50 patients in each. Patients received etiotropic antiviral therapy with riamilovir, 1 capsule (250 mg) 3 times a day for 5 days in the first group, in the second group patients received riamilovir in the “off label” regimen, 1 capsule (250 mg) 5 times a day for 5 days, and the third group consisted of 50 patients who received only pathogenetic treatment. The etiotropic antiviral drug riamilovir demonstrated clinical efficacy when used in both treatment regimens in patients with ARVI and a good safety profile
Keywords
##plugins.themes.academic_pro.article.details##

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
- Sabitov A.U., Kovtun O.P., Batskalevich N.A., Maltsev O.V., Zhdanov K.V., Esaulenko E.V., Tikhonova E.P., Kalinina Yu.S., Sorokin P.V., Chepur S.V., Stepanov A.V. Meta-analysis of randomized controlled clinical trials of the efficacy of Riamilovir in the etiotropic therapy of acute respiratory viral infection. Antibiotics and chemotherapies. 2021; 66 (5–6): 48–57. 2. Lazareva N.B., Zhuravleva M.V., Panteleeva L.R. ARVI: rational pharmacotherapy from the standpoint of clinical pharmacology. Medical Council. 2016; 4: 68–73. doi: https://doi.org/10.21518/2079-701x-2016- 4-68-73. 3. Lioznov D.A., Tokin I.I., Zubkova T.G., Sorokin P.V. Practice of using a domestic antiviral drug in etiotropic therapy of acute respiratory viral infection. Therapeutic archive. 2020; 4. Tokin I.I., Zubkova T.G., Drozdova Yu.V., Lioznov D.A. Experience of etiotropic therapy of ARVI with a domestic antiviral drug. Infectious diseases. 2019; 17 (4) 5. Yukhno M.V., Kolesnikov S.V., Gornostaeva Zh.A., Sidorchuk S.N. Organization of inpatient care during the 2016 influenza and acute respiratory viral infections epidemic in Veliky Novgorod. Journal of Infectology. 2016; 8 (4): 79–87.